JP2021521849A5 - - Google Patents

Info

Publication number
JP2021521849A5
JP2021521849A5 JP2020560338A JP2020560338A JP2021521849A5 JP 2021521849 A5 JP2021521849 A5 JP 2021521849A5 JP 2020560338 A JP2020560338 A JP 2020560338A JP 2020560338 A JP2020560338 A JP 2020560338A JP 2021521849 A5 JP2021521849 A5 JP 2021521849A5
Authority
JP
Japan
Prior art keywords
foxp3
sequence
promoter
locus
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020560338A
Other languages
English (en)
Japanese (ja)
Other versions
JP7575949B2 (ja
JP2021521849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/029159 external-priority patent/WO2019210078A1/en
Publication of JP2021521849A publication Critical patent/JP2021521849A/ja
Publication of JP2021521849A5 publication Critical patent/JP2021521849A5/ja
Priority to JP2024182444A priority Critical patent/JP7844581B2/ja
Application granted granted Critical
Publication of JP7575949B2 publication Critical patent/JP7575949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020560338A 2018-04-27 2019-04-25 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現 Active JP7575949B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024182444A JP7844581B2 (ja) 2018-04-27 2024-10-18 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862663561P 2018-04-27 2018-04-27
US62/663,561 2018-04-27
US201862773414P 2018-11-30 2018-11-30
US62/773,414 2018-11-30
PCT/US2019/029159 WO2019210078A1 (en) 2018-04-27 2019-04-25 Expression of human foxp3 in gene edited t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024182444A Division JP7844581B2 (ja) 2018-04-27 2024-10-18 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現

Publications (3)

Publication Number Publication Date
JP2021521849A JP2021521849A (ja) 2021-08-30
JP2021521849A5 true JP2021521849A5 (https=) 2022-11-25
JP7575949B2 JP7575949B2 (ja) 2024-10-31

Family

ID=68295504

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560338A Active JP7575949B2 (ja) 2018-04-27 2019-04-25 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現
JP2024182444A Active JP7844581B2 (ja) 2018-04-27 2024-10-18 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024182444A Active JP7844581B2 (ja) 2018-04-27 2024-10-18 遺伝子編集ｔ細胞におけるヒトｆｏｘｐ３の発現

Country Status (10)

Country Link
US (1) US20210253652A1 (https=)
EP (1) EP3784689A4 (https=)
JP (2) JP7575949B2 (https=)
KR (1) KR102912481B1 (https=)
CN (1) CN112041334A (https=)
AU (2) AU2019257708B2 (https=)
CA (1) CA3091491A1 (https=)
IL (1) IL277036A (https=)
SG (1) SG11202007877SA (https=)
WO (1) WO2019210078A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042179A1 (en) * 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
AU2019261438B2 (en) 2018-04-27 2024-08-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of FOXP3 in edited CD34+ cells
EP3921427A1 (en) * 2019-02-05 2021-12-15 Institut National de la Santé et de la Recherche Médicale (INSERM) Recombinant vectors suitable for the treatment of ipex syndrome
JP2022533713A (ja) * 2019-05-21 2022-07-25 サンガモ セラピューティクス， インコーポレイテッド 調節性ｔ細胞における制御された導入遺伝子発現
JP2023501388A (ja) * 2019-11-08 2023-01-18 サンガモ セラピューティクス， インコーポレイテッド 操作された制御性ｔ細胞の生成
EP4103591A4 (en) * 2020-02-13 2024-09-04 The Board of Trustees of the Leland Stanford Junior University Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients
AU2021373326A1 (en) * 2020-11-09 2023-06-22 Quell Therapeutics Ltd Method for cryopreserving engineered tregs
EP4355879A4 (en) * 2021-06-14 2025-07-23 Kamau Therapeutics Inc METHODS FOR GENETIC MODIFICATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR ERYTHROCYTE-SPECIFIC EXPRESSION OF THERAPEUTIC PROTEINS
WO2023122099A2 (en) * 2021-12-21 2023-06-29 The Board Of Trustees Of The Leland Stanford Junior University Crispr-based gene editing to preserve splicing and expression of foxp3 isoforms 1 and 2
CN115305237B (zh) * 2022-07-08 2023-07-14 中南大学 一种优化的调节性t细胞的扩增及规模化生产的方法
EP4634383A1 (en) * 2022-12-16 2025-10-22 Life Edit Therapeutics, Inc. Guide rnas that target foxp3 gene and methods of use
AU2024308500A1 (en) * 2023-06-24 2025-12-18 Sonoma Biotherapeutics, Inc. Compositions and methods for engineering cells
WO2025054503A1 (en) * 2023-09-08 2025-03-13 Sonoma Biotherapeutics, Inc. Cells ectopically expressing foxp3
JP7818147B1 (ja) * 2025-01-23 2026-02-20 国立研究開発法人国立がん研究センター エフェクターｔ細胞、およびそれを含む医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008101272A1 (en) * 2007-02-21 2008-08-28 Women's And Children's Health Research Institute Inc Method for obtaining treg-cells
ES2883131T3 (es) * 2013-05-29 2021-12-07 Cellectis Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN
WO2016123578A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
CN107921148A (zh) * 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
MA45996A (fr) * 2016-08-16 2021-06-02 Bluebird Bio Inc Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
WO2018073391A1 (en) * 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
AU2017347854B2 (en) * 2016-10-27 2022-12-08 Intima Bioscience, Inc. Viral methods of T cell therapy
CA3042179A1 (en) 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
CN109790518A (zh) * 2017-05-08 2019-05-21 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
WO2019040655A1 (en) * 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
AU2019261438B2 (en) 2018-04-27 2024-08-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Expression of FOXP3 in edited CD34+ cells

Similar Documents

Publication Publication Date Title
JP2021521849A5 (https=)
JP2021521856A5 (https=)
AU2021277627B2 (en) Anti-CD70-chimeric antigen receptors
KR102859521B1 (ko) 지속 치료를 위한 나노입자 조성물
TWI863887B (zh) 使用具有工程化穩定表現內源性foxp3基因之cd4 t細胞治療自體免疫疾病的方法
US20190322983A1 (en) Engineered treg cells
JP2025013879A5 (https=)
JP2018512151A5 (https=)
Perzova et al. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia
JP2020529834A5 (https=)
AU2018336522A1 (en) A gRNA targeting HPK1 and a method for editing HPK1 gene
KR20200018572A (ko) 시험관 내에서 Ｔ 세포 내 표적 유전자를 녹아웃시키는 방법 및 그 방법에 이용되는 ｃｒＲＮＡ
AU2022312508A1 (en) Polycistronic vectors for cell-based therapies
Lu et al. Dynamic changes in the regulatory T-cell heterogeneity and function by murine IL-2 mutein
JP2024514355A5 (https=)
JP2025532839A (ja) 細胞に基づく治療を増強させるための抗体耐性改変受容体
Lantow et al. The granulocyte colony stimulating factor pathway regulates autoantibody production in a murine induced model of systemic lupus erythematosus
US20240307444A1 (en) Methods and compositions for improved immunotherapies
US20250195572A1 (en) Methods and compositions comprising fusion proteins for improved immunotherapies
US20240252642A1 (en) Hypoimmunogenic rhd negative primary t cells
Huang et al. MHC class I allele diversity in cynomolgus macaques of Vietnamese origin
JP2023052688A (ja) 対合が改善されたｔ細胞受容体ｔ細胞
US20230272431A1 (en) Methods and compositions for editing the b2m locus in b cells
Fox Towards Gene Therapy for CTLA4 Insufficiency
EP4384615A2 (en) Engineering cells for cell-based therapies, and associated compositions and methods